HIG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HIG is not a good buy right now for a beginner long-term investor with capital to deploy immediately. The stock has decent fundamental support from analyst Outperform/Buy ratings and strong capital-return sentiment in the industry, but the current technical setup is weak, insider selling is elevated, and near-term price behavior looks soft. If you want to be fully invested now, this is a hold rather than a buy.
HIG is in a short-term bearish trend. MACD histogram is -0.302 and still expanding negatively, which confirms downside momentum. The moving-average structure is bearish with SMA_200 > SMA_20 > SMA_5, showing the stock is trading below a weakening trend stack. RSI_6 at 20.854 suggests the stock is oversold, but not yet showing a clear reversal signal. Price at 128.97 is below the pivot at 133.42 and sitting near the S2 level of 128.149, so the chart is vulnerable despite being close to short-term support. The pattern-based estimate also points to slightly negative forward returns over the next day, week, and month.
Analyst ratings remain broadly constructive overall, with multiple firms keeping Outperform/Overweight/Buy views. Raymond James said Hartford should generate above-peer ROEs through 2027, supported by leadership in U.S. small commercial insurance, disciplined underwriting, and stable combined ratios. Hedge funds are also buying aggressively, with buying up 324.87% over the last quarter. The insurance sector is seeing strong shareholder-return activity from peers, which can reinforce investor confidence in the group.
Recent analyst target cuts show some caution after the Q1 miss, especially around reserve adequacy and higher expense ratios. The Q1 result was hurt by a legacy reserve charge, and several firms mentioned sluggish premium growth. Insider selling has surged sharply, up 4334.85% over the last month, which is a meaningful negative signal. Technically the stock is weak, and the stock trend model points to further short-term downside. There is also no direct event-driven catalyst specifically for HIG in the news items provided.
No latest-quarter financial statement data was provided in a usable format, so a direct quarter-by-quarter revenue/earnings growth assessment cannot be made here. The only financial commentary available is analyst-based: Hartford’s Q1 results missed expectations due to a legacy reserve charge and higher expense ratios, while analysts still expect above-peer ROEs through 2027 and describe underwriting quality and combined ratios as relatively stable.
Analyst sentiment is still mostly positive, but the trend in price targets has been drifting slightly lower after the Q1 miss. Raymond James lowered its target to 150 from 160 and kept Outperform; Mizuho raised to 159 from 158 and kept Outperform; UBS lowered to 155 from 157 and kept Buy; Barclays lowered to 156 from 159 and kept Overweight; BofA is Neutral at 138; Cantor Fitzgerald lowered to 160 from 165 and kept Overweight; Keefe Bruyette downgraded to Market Perform from Outperform with a 149 target due to reserve concerns. Wall Street is basically constructive on the business quality and capital generation, but more cautious on reserve risk and near-term execution.
